HaroldN.KeerMD

PubMed

• 8 citations
  Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
  Jonathan W. Riess, Karen L. Reckamp, Paul Frankel, Jeffrey Longmate, Karen Kelly, David R. Gandara, Caroline M. Weipert, Victoria M. Raymond, Harold N. Keer, Philip C....> ;Clinical Lung Cancer. 2021 May 15
• 20 citations
  A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
  Costantine Albany, Zeeshan Fazal, Ratnakar Singh, Emmanuel Bikorimana, Nabil Adra, Nasser H. Hanna, Lawrence H. Einhorn, Susan M. Perkins, George E. Sandusky, Brock C....> ;Cancer Medicine. 2021 Jan 1
• 13 citations
  Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
  Haley E. Ramsey, Aram Oganesian, Agnieszka E. Gorska, Londa Fuller, Kelli L. Boyd, Harold N. Keer, Mohammad Azab, Michael R. Savona> ;Targeted Oncology. 2020 Apr 1
• 42 citations
  A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
  Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad A. Ghamande, M...> ;Clinical Cancer Research. 2020 Mar 1
• 59 citations
  Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
  Guillermo Garcia-Manero, Gail J. Roboz, Katherine Walsh, Hagop M. Kantarjian, Ellen K. Ritchie, Patricia Kropf, Casey O'Connell, Raoul Tibes, Scott D. Lunin, Todd L. R...> ;The Lancet. Haematology. 2019 Jun 1
• 9 citations
  A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
  Manjusha Thakar, Yue Hu, Michael Morreale, Lane Lerner, Wan Ying Lin, Rupashree Sen, Yi Cai, Enusha Karunasena, Maya Thakar, Soren Saggi, Harold N. Keer, Nita Ahuja> ;Plos One. 2018 Jun 21
• 80 citations
  An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
  Nicholas Pulliam, Fang Fang, Ali R. Özeş, Jessica Tang, Adeoluwa Adewuyi, Harold N. Keer, John Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V...> ;Clinical Cancer Research. 2018 Jul 1
• 70 citations
  Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs
  Fang Fang, Horacio Cardenas, Hao Huang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Harold N. Keer, Yunlong Liu, Kenneth P. Nephew, Daniela Matei> ;Cancer Research. 2017 Jan 1
• 23 citations
  Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointesti...
  Andrew J. Wagner, Mark Agulnik, Michael Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret von Mehren, Jonathan C. Trent, George D. Demetri, Christopher L. Corles...> ;European Journal of Cancer. 2016 Jul 1
• 67 citations
  A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
  Anthony W. Tolcher, Kyri Papadopoulos, Amita Patnaik, K. Wilson, S. Thayer, J. Zanghi, A.T. Gemo, W.M. Kavanaugh, Harold N. Keer, Patricia LoRusso> ;Annals of Oncology. 2016 Mar 1
• 15 citations
  Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
  Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Daniel C Rabe, Fabiola Cecch...> ;Investigational New Drugs. 2015 Dec 1
• O3.6Combination of HSP90 inhibitor onalespib with crizotinib to treat or delay resistance in NSCLC: Preclinical and Clinical Investigations.
  Keer, H.,Smyth, T.,Courtin, A.,Hearn, K.,Lyons, J.,Wallis, N.,Oganesian, A.,Azab, M.> ;Ann. Oncol.. 2015 Mar 22
• A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
  Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Lorusso P> ;Invest New Drugs. 2013-06-01
• 56 citations
  Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
  Tanguy Y. Seiwert, John Sarantopoulos, Howard Kallender, Stewart W. McCallum, Harold Keer, George R. Blumenschein> ;Investigational New Drugs. 2013 Apr 1
• 150 citations
  A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
  Joseph Paul Eder, Geoffrey I. Shapiro, Leonard Joseph Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Hitchcock-Bryan S, Laurie Sherman,...> ;Clinical Cancer Research. 2010 Jul 1
• 13 citations
  DNA profile of nephrogenic adenoma assessed by flow cytometry.
  Franklin Gaylis, Harold N. Keer, Kenneth D. Bauer, James M. Kozlowski, John T. Grayhack> ;Urology. 1993 Feb 1
• 34 citations
  Components of the plasminogen-plasmin system in human tumor cell lines.
  Hau C. Kwaan, Harold N. Keer, James A. Radosevich, Jean-Francois Cajot, Robin Ernst> ;Seminars in Thrombosis and Hemostasis. 1991 Jul 1
• 49 citations
  Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
  Harold N. Keer, Franklin Gaylis, James M. Kozlowski, Hau C. Kwaan, Kenneth D. Bauer, Akhouri A. Sinha, Michael J. Wilson> ;The Prostate. 1991 Jan 1
• 62 citations
  Fibrinolysis and cancer.
  Hau C. Kwaan, Harold N. Keer> ;Seminars in Thrombosis and Hemostasis. 1990 Jul 1
• 77 citations
  Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo.
  Harold N. Keer, James M. Kozlowski, Yvonne Tsai, Chung Lee, Robert N. McEwan, John T. Grayhack> ;The Journal of Urology. 1990 Feb 1
• 82 citations
  Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype
  Franklin Gaylis, Harold N. Keer, Michael J. Wilson, Hau C. Kwaan, Akhouri A. Sinha, James M. Kozlowski> ;The Journal of Urology. 1989 Jul 1
• Join now to see all

Abstracts/Posters

• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Harold N. Keer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019